Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

RXRX 12.20.2024

Full Press ReleaseSEC FilingsOur RXRX Tweets

About Gravity Analytica

Recent News

  • 01.13.2025 - 43nd Annual J.P. Morgan Healthcare Conference
  • 01.07.2025 - Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
  • 01.06.2025 - Recursion to Present at 43rd Annual JP Morgan Healthcare Conference

Recent Filings

  • 01.17.2025 - 144 Report of proposed sale of securities
  • 01.13.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.13.2025 - EX-99.1 EX-99.1
PDF Version

Salt Lake City, Utah,Dec. 20, 2024(GLOBE NEWSWIRE) --Recursion Pharmaceuticals, Inc.(“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that onDecember 19, 2024, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 7,952,836 shares of its class A common stock in the aggregate to 230 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award was granted as an inducement material to the employee's commencement of employment with a subsidiary of Recursion in connection with Recursion's acquisition ofExscientia plcand pursuant to Nasdaq Listing Rule 5635(c)(4).

Each inducement RSU award will vest as to 1/16th of the shares subject to the award quarterly on each ofFebruary 15,May 15,August 15, andNovember 15, beginning withFebruary 15, 2025until the inducement RSU award is fully vested, subject to the inducement RSU award recipient’s continued employment through the Company Vesting Dates. Each inducement RSU award is subject to the terms and conditions of the 2024 Plan and the grant agreements covering the awards.

AboutRecursion Pharmaceuticals

Recursion Pharmaceuticals, Inc.(NASDAQ: RXRX) is a leading clinical stage TechBio company decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously generate one of the world’s largest proprietary biological and chemical datasets. Recursion leverages sophisticated machine-learning algorithms to distill from its dataset a collection of trillions of searchable relationships across biology and chemistry unconstrained by human bias. By commanding massive experimental scale — up to millions of wet lab experiments weekly — and massive computational scale — owning and operating one of the most powerful supercomputers in the world, Recursion is uniting technology, biology and chemistry to advance the future of medicine.

Recursion is headquartered inSalt Lake City, where it is a founding member of BioHive, theUtahlife sciences industry collective. Recursion also has offices inToronto,Montréal,New York,London,Oxfordarea, and theSan Francisco Bayarea. Learn more atwww.Recursion.com, or connect on X (formerly Twitter) and LinkedIn.

Media ContactMedia@Recursion.com

Investor ContactInvestor@Recursion.com

Ryan KellyRecursion Pharmaceuticalsmedia@recursion.com

Recursion Pharmaceuticals

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com